Case Report: Complete pathologic response in advanced melanoma with SFRT and dual checkpoint inhibition
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for advanced melanoma, though response rates remain limited in bulky disease. Herein, we report the case of a complete pathologic response following combination spatially fractionated radiation therapy (SFRT) and dual nivolumab and ipilimumab for a 12 cm right lung melanoma mass, with subsequent lobectomy revealing no viable tumor cells. Now disease free 2.5 years after treatment, including more than 1 year off all systemic therapy, this case highlights the potential synergy between SFRT and immunotherapy in advanced melanoma management.
Authors
- Sean S. Park (ORCID: https://orcid.org/0000-0003-3814-853X)
- Michael P. Grams (ORCID: https://orcid.org/0000-0002-9873-6926)
- Kimberly S. Corbin (ORCID: https://orcid.org/0000-0002-3880-9791)
- Jared Hobson
- Haidong Dong (ORCID: https://orcid.org/0000-0002-5782-2983)
- Joanina K. Gicobi (ORCID: https://orcid.org/0000-0002-2741-0363)
- Lisa A. Kottschade (ORCID: https://orcid.org/0000-0001-8922-2619)
- Dennis A. Wigle (ORCID: https://orcid.org/0000-0003-2407-1340)
- Svetomir N. Markovic (ORCID: https://orcid.org/0000-0002-9238-4325)
- Lindsey A Durham
Institutions
- Mayo Clinic (US)
- WinnMed (US)
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-17
- DOI
- https://doi.org/10.3389/fonc.2025.1697902
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00